“A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) AS MONOTHERAPY AND IN COMBINATION WITH BALSTILIMAB (AGEN2034) FOR THE TREATMENT OF ADVANCED, REFRACTORY MICROSATELLITE STABLE COLORECTAL CANCER WITHOUT LIVER METASTASES”
Principal Investigator
Chao Yin, MDLocations
Fairfax Office
Gainesville Office
Learn More About This Trial
Other Relevant Trials
“A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01)”
Principal Investigator
Alexander I. Spira, MD, PhD, FACPA Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination With Pembrolizumab in Subjects With Locally Advanced/Metastatic Solid Tumors
